中西医结合在急诊治疗重症心力衰竭中的优势及对心脏射血能力的影响

以北京市垂杨柳医院急诊科2019年7月至2020年7月收治的急性重症心衰患者作为研究对象，通过回顾性平行对照临床研究，比较标准西医方案（对照组：螺内酯+卡托普利）与中西医联合方案（螺内酯+卡托普利+生脉饮）的疗效和预后，采用超声心动图检测心脏射血功能，指标包括：二尖瓣舒张早期流速/舒张晚期流速（E/A）、左室收缩末期内径（LVES）、左室舒张末期内径（LVED）、左室射血分数（LVEF）以及药物安全性及患者预后的生活质量量表（QOL）评分。结果发现，中西医组的E/A、LVEF高于对照组，而LVES、LVED低于对照组；中西医组的低血钾、咳嗽、高血钾等不良反应发生率低于对照组；中西医组预后的QOL评分高于对照组；说明生脉饮联合西医方案治疗急性重症心力衰竭具有一定的优势，可进一步改善心功能、增强左室射血能力，降低不良反应，改善患者预后生活质量。

Advantages of the integrated traditional Chinese and western medicine in emergency treatment of severe heart failure and the effects on cardiac ejection ability

Patients with acute severe heart failure treated in the emergency department of Chuiyangliu Hospital from July 2019 to July 2020 were taken as the research subjects in this retrospective parallel controlled clinical study to compare the efficacy and prognosis between the standard western medicine treatment (control group: spironolactone+captopril) and integrated traditional Chinese and western medicine treatment (integrated group: spironolactone+captopril+Shengmai Decoction). The cardiac ejection function was measured by echocardiography. The results showed that the E/A and LVEF of the integrated group were higher than those of the control group, while the LVES and LVED were lower than those of the control group; the incidence of adverse reactions such as hypokalemia, cough, and hyperkalemia in the integrated group was lower than that in the control group; the QOL score in the integrated group was higher than that in the control group. This suggests that Shengmaiyin combined with western medicine has certain advantage in the treatment of acute severe heart failure, which can further improve cardiac function, enhance left ventricular ejection ability, reduce adverse reactions and improve the prognosis and quality of life of patients.